Views & Analysis | Perspectives on pharma industry issues

R&D

pharmaphorum podcast Episode 266, Parexel - Paul Bridges and Charlotte Moser

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Sales & Marketing

Pharmacist reads doctor's notes with AI overlay concept in pharmacy

How pharma can make pharmacies a powerful marketing channel

Among POC marketing strategies, activating the pharmacy environment is especially powerful.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Market Access

Why 70% of pharma partnership spend misses patients

Finding a start-up or building an app is the cheap part; combining capabilities into something that scales across markets is the expensive part.

Oncology

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.

R&D

Reimagining biopharma: How AI is reshaping discovery, develo...

No longer confined to experimental pilots, AI is becoming a catalyst for change across the entire biopharma value chain - but there are challenges.

Sales & Marketing

Adjusting pharma marketing in the rise of community pharmaci...

Community pharmacies are accessible, trusted, and clinically capable care providers that are increasingly more influential in the patient journey.

Oncology

Interview at ESMO 2025 with EVERSANA's Barry Vucsko

ESMO25: Acceleration, accessibility, and accuracy, with Barr...

At ESMO25, pharmaphorum spoke with Barry Vucsko, Senior VP of Strategic Development, Agency Services, for the EVERSANA Oncology Centre of Excellence.

Sales & Marketing

How pharma can make pharmacies a powerful marketing channel

Among POC marketing strategies, activating the pharmacy environment is especially powerful.

Sales & Marketing

12 Questions with Shauna Lord

Shauna Lord recently joined GSK as Business Unit Head Specialty (UK Commercial) to lead the Specialty business in the UK.

Digital

How a Norwegian hospital unlocked capacity without adding st...

The question for healthcare leaders is less whether AI has a role in surgical planning, and more how to implement it best.

Digital

Integration: The key to scalable decentralised trials

Successful DCTs depend less on the technology deployed and more on how effectively those capabilities are integrated and executed.

Market Access

Why 70% of pharma partnership spend misses patients

Finding a start-up or building an app is the cheap part; combining capabilities into something that scales across markets is the expensive part.

Market Access

Industry exercises option for midpoint review of VPAG Invest...

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Oncology

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.

Oncology

CAR-T has a geography problem

The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now.

Patients

Designing global PSPs for the real world

How integrating strategic design with implementation expertise can help create more scalable, locally relevant, and effective global PSPs.

Patients

Is women’s health reaching an inflection point?

A half-day symposium – titled Women’s Health: From Intractable to Investable – was held in London on 11th June, organised by Weatherden.

Patients

Patient engagement drives clinical and commercial success

Engagement solutions can tap into long-lasting patient motivations that sustain behaviour.

Parexel: Flawless execution, policy shifts & patient-centric...

How pharma can make pharmacies a powerful marketing channel

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Why 70% of pharma partnership spend misses patients

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Reimagining biopharma: How AI is reshaping discovery, develo...

Adjusting pharma marketing in the rise of community pharmaci...

ESMO25: Acceleration, accessibility, and accuracy, with Barr...

How pharma can make pharmacies a powerful marketing channel

12 Questions with Shauna Lord

How a Norwegian hospital unlocked capacity without adding st...

Integration: The key to scalable decentralised trials

Why 70% of pharma partnership spend misses patients

Industry exercises option for midpoint review of VPAG Invest...

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

CAR-T has a geography problem

Designing global PSPs for the real world

Is women’s health reaching an inflection point?

Patient engagement drives clinical and commercial success

Parexel: Flawless execution, policy shifts & patient-centric...

Women in STEM: Overcoming exclusionary workplace culture

BIOSECURE and beyond: What it really means for pharma supply...

Drugmakers asked to defend Chinese trials; reports

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks